Market Overview

UPDATE: Piper Jaffray Raises PT on LHC Group on Q4 Earnings, FY13 EPS Guidance

Related LHCG
Top 4 NASDAQ Stocks In The Home Health Care Industry With The Highest EPS
Top 4 Small-Cap Stocks In The Home Health Care Industry With The Highest EPS
Quest Diagnostics (DGX) Tops Q1 Earnings, Keeps '15 View - Analyst Blog (Zacks)

In a report published Monday, Piper Jaffray reiterated its Overweight rating on LHC Group (NASDAQ: LHCG), and slightly raised its price target from $21.00 to $22.00.

Piper Jaffray noted, “Organic admissions growth of 5.6% was solid and the company continues to receive an increasing amount of inbound calls about hospital partnership opportunities. Although the recently completely Addus Home Health acquisition is expected to be neutral to FY13 earnings, we believe Addus could approach corporate margins in 2014 and accretion could be in the neighborhood of $0.20-$0.25 assuming 100 bps of overall G&A leverage.”

LHC Group closed on Friday at $20.35.

Latest Ratings for LHCG

Feb 2015Credit SuisseMaintainsOutperform
Dec 2014Credit SuisseUpgradesUnderperformOutperform
Nov 2014BairdUpgradesUnderperformNeutral

View More Analyst Ratings for LHCG
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Price Target Analyst Ratings


Related Articles (LHCG)

Around the Web, We're Loving...